Somalia’s cancer diagnosis system emerged from decades of disruption with major gaps still intact
Somalia’s pathology services have spent 35 years under pressure from conflict, instability, and repeated interruptions in infrastructure. The resulting diagnostic deficit has not been abstract; it has shaped whether cancers are identified accurately, staged appropriately, and treated in time. In this mixed-methods assessment of south Somalia between 1991 and 2025, investigators documented a system that has expanded from near-collapse to a fragile but functioning network, while still lacking many of the tools that define modern cancer diagnosis.
Nine operational histopathology laboratories were identified, employing 14 practising pathologists and collectively processing an estimated 25,000–30,000 histopathology specimens each year. The expansion was strikingly uneven. Only one laboratory was operating before 2015, and the number rose to nine by 2025, a change that followed the establishment of the Mogadishu Somali-Türkiye Training and Research Hospital in 2015. In practical terms, this means pathology capacity is no longer confined to a single point of access, but the system still depends on a narrow professional base and a limited diagnostic toolkit.
Histopathology is available; advanced cancer diagnostics remain scarce
Cancer diagnosis begins with tissue, but accurate classification often requires more than routine microscopy. In this study, immunohistochemistry was available in only one laboratory, while frozen section and molecular diagnostic services were unavailable nationwide. Those omissions matter because modern oncology increasingly relies on biomarker-driven diagnosis, confirmation of tumor lineage, and rapid intraoperative decision-making. Without immunohistochemistry, many lesions remain difficult to subclassify; without molecular testing, precision oncology, prognostic stratification, and targeted treatment selection remain out of reach.
The diagnostic bottleneck is structural rather than purely technical. Even with more laboratories in operation, the network cannot yet deliver the layered testing that supports reliable cancer care in higher-resource settings. For pathologists, the consequence is a heavier dependence on morphology alone, often in settings where specimen quality, fixation, transport, and reagent stability are already compromised. For clinicians, the consequence is delayed or incomplete diagnosis, with downstream effects on surgery, oncology referral, and treatment planning.
Reagent shortages and infrastructure deficits still shape daily pathology work
The qualitative interviews brought that fragility into view. Four major themes dominated: inadequate laboratory infrastructure and recurrent reagent shortage; workforce and specialist training limitations; restricted access to advanced diagnostic technologies; and the need for better quality assurance, multidisciplinary collaboration, and national coordination. These themes point to a system in which progress is real but still vulnerable to supply interruptions and institutional fragmentation.
Reagent shortages can interrupt staining, delay reporting, and reduce confidence in results. Limited infrastructure can make it difficult to maintain specimen integrity or provide reliable turnaround times. Training gaps affect not only diagnostic accuracy, but also the ability to expand services sustainably and standardize practice across institutions. In a field where subtle morphologic distinctions can alter a cancer diagnosis, the absence of stable laboratory inputs is a direct threat to patient care.
One laboratory can no longer carry the diagnostic burden of an entire country.
Workforce growth has not yet matched diagnostic need
The presence of 14 practising pathologists across nine laboratories suggests a visible recovery in human capacity, yet it also reveals how thin the workforce remains. Pathology is a specialty that depends on continuity, mentorship, and technical depth. When specialists are few, every absence is amplified and every service gap becomes harder to absorb. The study’s emphasis on specialist training limitations is particularly important because rebuilding pathology is not only a matter of equipment procurement; it requires an expert workforce able to interpret complex cases, supervise laboratories, and train the next generation.
The broader clinical implication is straightforward. Cancer control cannot mature faster than the diagnostic workforce that supports it. Without enough trained pathologists, laboratories may process specimens, but they cannot reliably deliver the interpretive precision needed for treatment decisions.
The first histopathology-based cancer registry changes the surveillance equation
In 2024, the Banadir region established Somalia’s first histopathology-based cancer registry. That development marks a substantial shift from isolated diagnostic activity toward systematic cancer surveillance. Registries convert routine pathology work into population-level data, allowing health systems to track disease patterns, estimate burden, and plan services with greater accuracy. In a country where conflict has repeatedly disrupted health information systems, the creation of a pathology-based registry provides a foundation for national cancer surveillance that did not previously exist.
This is more than an administrative milestone. Registry data can expose which cancers are most common, where diagnostic access is weakest, and how pathology services should be distributed. It can also help national planners justify investments in reagents, staffing, equipment, and referral pathways. Without surveillance, pathology capacity may grow in isolation from the actual cancer burden. With surveillance, diagnostic rebuilding can become more targeted and accountable.
National cancer planning now depends on sustained investment, not isolated gains
The study makes clear that Somalia has rebuilt meaningful pathology capacity despite decades of instability. The network is larger, more organized, and more visible than it was a decade ago. Yet the remaining gaps are substantial enough to limit equitable cancer diagnosis across the country. Advanced diagnostics are sparse, quality systems need reinforcement, and coordination across laboratories remains incomplete.
The clinical stakes are immediate. A cancer diagnosis that is delayed, incomplete, or imprecise can shift a patient from potentially curative treatment to palliative care, or leave clinicians without the information needed to select therapy. In resource-constrained and conflict-affected settings, pathology is not a background service; it is the point at which cancer care either becomes actionable or stalls.
The experience in Somalia offers a wider lesson for health systems recovering from instability. Laboratory reconstruction can begin with physical reopening and staffing, but durable cancer diagnosis requires reagent security, diagnostic expansion, professional training, quality assurance, and surveillance infrastructure. This report stops short of showing how quickly those investments can be scaled nationwide, but it makes the central constraint unmistakable: diagnosis will remain uneven until the system can support advanced testing, coordinated oversight, and a larger specialist workforce.